Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-SARS-CoV-2 Serum for Early COVID-19
NCT04834089Phase 2Unknown
- Sponsor
- Instituto Butantan
- Start
- May 2021
- Primary completion
- May 2022
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Instituto Butantan. Primary endpoints: Frequency of local and systemic adverse events at 12 hours, Anti-SARS-CoV-2 serum average life at 28 days and 1 more. Status: unknown.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04834089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04834089.